FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 360:833-836 February 19, 2009 Number 8 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Karapetis, C. S. PubMed Citation

To the Editor: Karapetis et al. (Oct. 23 issue)¹ investigated K-ras mutations by means of direct sequencing of polymerase-chain-reaction (PCR) products. The detection of low-prevalence mutations by means of direct sequencing is problematic.² Very sensitive techniques, including the Amplification Refractory Mutation System (ARMS) with the Scorpions real-time PCR technique (DxS) and mutation-enriched sequencing,³ are now available. We have compared direct sequencing with mutation-enriched sequencing in 90 colorectal carcinomas. The prevalence of tumors harboring K-ras mutations was 40% by means of direct sequencing and 55% by means of mutation-enriched sequencing. Thus, we found mutations in minor clones in about 15% of . . . [Full Text of this Article]

This article has been cited by other articles:

• Whitehall, V., Tran, K., Umapathy, A., Grieu, F., Hewitt, C., Evans, T.-J., Ismail, T., Li, W. Q., Collins, P., Ravetto, P., Leggett, B., Salto-Tellez, M., Soong, R., Fox, S., Scott, R. J., Dobrovic, A., Iacopetta, B. (2009). A Multicenter Blinded Study to Evaluate KRAS Mutation Testing Methodologies in the Clinical Setting. J. Mol. Diagn. 11: 543-552 [Abstract] [Full Text]